Macrophages loaded with doxorubicin by ATP-mediated permeabilization: Potential carriers for antitumor therapy

Abstract

In many cell types extracellular ATP (ATP e) has been shown to cause reversible plasma membrane permeabilization to low molecular weight (< 900 Da) water-soluble compounds. In the present report we have exploited this technique to incorporate the anticancer drug doxorubicin (DXR), molecular mass 543 Da, into the cytoplasm of two mouse cell lines that had previously been shown to express the ATP e-gated pore, J774 macrophages and tumor necrosis factor (TNF)-resistant L929 fibroblasts. Compared to passively loaded cells, ATP e-mediated reversible permeabilization allowed an at least 4-fold increase in DXR intracellular trapping (0.5 pg/cell versus 2 pg/cell). Analysis of the release kinetics at 37°C showed that about 40% of total intracellular DXR was discharged during the first hour from both ATP e-permeabilized and passively loaded cells; about 15% further release was observed upon incubation up to 4 h. DXR release profiles were similar in ATP e-permeabilized and passively loaded cells. ATP e-permeabilized, DXR-loaded (ATP e-DXR) cells strongly inhibited the proliferation of K562 tumor cells. Taken together these results indicate that ATP e-mediated reversible plasma membrane permeabilization can be effectively used to load cells of different histotypes with high concentrations of DXR. This approach could permit to vehicle high doses of anticancer agents by using living cells while reducing systemic toxic effects.